



Dear Industry Partners,

Thank you for your support and interest in partnering with CIRC. CIRC has developed a process to expedite review of industry-supported national or international investigator-initiated studies seeking CIRC endorsement and member participation. Industry partners are asked to kindly submit a 1-2-page synopsis of the proposed study to the President of CIRC that includes all of the following elements:

1. Study purpose/question(s)/hypotheses
2. Basic background and rationale
3. Overview of study methods (including patients, interventions, outcomes, and protocol)
4. Funding support that will be provided to carry out all study-related tasks
5. Number of study sites, investigators and participants sought from CIRC
6. Specific requests for CIRC resources (e.g. research and/or administrative support)
7. Study timeline
8. Current steering committee members and participating countries/centers
9. Whether the lead Canadian investigator from CIRC would be eligible to be part of the steering committee and/or be recognized as a key author in the masthead of the eventual publication(s)
10. Whether CIRC would be recognized as a contributing body in the eventual publication(s), in which site investigators could be recognized as co-authors as part of a CIRC group authorship

Proposals may be submitted to CIRC at any time during the year. Each proposal will be evaluated by the Scientific Committee within 90 days of submission, based on scientific merit, feasibility, funding, and suitability to CIRC's mission. A final decision as to whether CIRC will be able to support the study, along with reviewers' comments and Scientific Officer's notes, will be provided to the Scientific Lead from the industry partner.

Proposals that are considered to have sufficient merit will be put forth by the Executive Committee to the broader CIRC membership to seek feedback from the membership and a study champion. If multiple individuals express interest, the Executive Committee will decide upon the most suitable study lead, with a preference towards early career investigators. The chosen study lead will be responsible for soliciting study sites and co-investigators across the CIRC membership to participate in the study and to develop a plan to execute the study across Canada, in collaboration with the industry partner's scientific team and the CIRC Executive Committee.

We look forward to working together!

Sincerely,

Talat Bessissow, MDCM, MSc, FRCPC
President
CIRC

Kate Lee, PhD, MBA
VP, Research & Patient Programs
Crohn's and Colitis Canada